IDEAL Data Expands Gilead’s Livdelzi Evidence Into Lower-ALP PBC Population Scrip Pharma Intelligence 15:41 Wed, 03 Jun
Gilead eyes PBC expansion for Livdelzi on positive one-year data Clinical Trials Arena 11:55 Wed, 03 Jun
Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population FiercePharma 16:03 Tue, 02 Jun
Gilead Sciences Reports Positive Results From Phase 3 Study Of Livdelzi For Biliary Cholangitis RTT News 14:20 Tue, 02 Jun
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 ideal Trial in Primary Biliary Cholangitis (Pbc) Business Wire (Press Release) 13:36 Tue, 02 Jun
Phase 3 assure Interim Data: Majority of People in the Study with ALP 1–1.67×Uln Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) Business Wire (Press Release) 07:09 Wed, 27 May
